Wedbush Predicts Xencor’s FY2024 Earnings (NASDAQ:XNCR)

Xencor, Inc. (NASDAQ:XNCR) – Investment analysts at Wedbush raised their FY2024 EPS estimates for Xencor in a report released on Thursday, November 7th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will earn ($3.64) per share for the year, up from their prior estimate of ($3.87). Wedbush currently has a “Outperform” rating and a $38.00 price target on the stock. The consensus estimate for Xencor’s current full-year earnings is ($3.91) per share. Wedbush also issued estimates for Xencor’s Q4 2024 earnings at ($0.75) EPS, Q1 2025 earnings at ($0.82) EPS, Q2 2025 earnings at ($0.81) EPS, Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.82) EPS, FY2025 earnings at ($3.27) EPS, FY2026 earnings at ($3.33) EPS, FY2027 earnings at ($3.42) EPS and FY2028 earnings at ($4.25) EPS.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.98) by $0.27. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business had revenue of $10.70 million during the quarter, compared to the consensus estimate of $14.59 million. During the same quarter in the prior year, the firm earned ($0.40) EPS. The business’s revenue was down 81.9% on a year-over-year basis.

A number of other research firms have also weighed in on XNCR. BMO Capital Markets reissued an “outperform” rating and issued a $34.00 target price (up from $32.00) on shares of Xencor in a report on Friday, November 8th. JPMorgan Chase & Co. lifted their price objective on shares of Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Finally, Royal Bank of Canada upped their target price on shares of Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a research report on Thursday, September 26th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Xencor has a consensus rating of “Moderate Buy” and a consensus target price of $35.75.

Xencor Stock Performance

NASDAQ XNCR opened at $23.71 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.92. Xencor has a 1-year low of $15.31 and a 1-year high of $26.84. The business has a 50 day simple moving average of $20.70 and a two-hundred day simple moving average of $20.34. The stock has a market capitalization of $1.66 billion, a PE ratio of -7.41 and a beta of 0.66.

Institutional Trading of Xencor

Several institutional investors have recently added to or reduced their stakes in the company. Quarry LP purchased a new stake in shares of Xencor in the second quarter worth approximately $36,000. KBC Group NV increased its stake in Xencor by 63.5% in the third quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 1,213 shares during the period. SG Americas Securities LLC bought a new stake in shares of Xencor during the second quarter worth $154,000. XTX Topco Ltd purchased a new stake in shares of Xencor during the second quarter valued at $196,000. Finally, Acadian Asset Management LLC bought a new position in shares of Xencor in the first quarter worth about $206,000.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.